1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Androgen Antagonists -Pipeline Insights, 2017


DelveInsight’s, “Androgen Antagonists-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Androgen Antagonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Androgen Antagonists. DelveInsight’s Report also assesses the Androgen Antagonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Androgen Antagonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Androgen Antagonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Androgen Antagonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Androgen Antagonists -Pipeline Insights, 2017
Illustrative

- Androgen Antagonists Overview
- Androgen Antagonists Disease Associated
- Androgen Antagonists Pipeline Therapeutics
- Androgen Antagonists Therapeutics under Development by Companies
- Androgen Antagonists Filed and Phase III Products
- Comparative Analysis
- Androgen Antagonists Phase II Products
- Comparative Analysis
- Androgen Antagonists Phase I and IND Filed Products
- Comparative Analysis
- Androgen Antagonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Androgen Antagonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Androgen Antagonists - Discontinued Products
- Androgen Antagonists - Dormant Products
- Companies Involved in Therapeutics Development for Androgen Antagonists
- Appendix
- Methodology
- Contact Us
- Disclaimer



List of Tables

- Number of Products under Development for Androgen Antagonists by Therapy Area, 2017
- Number of Products under Development for Androgen Antagonists, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Androgen Antagonists Assessment by Monotherapy Products
- Androgen Antagonists Assessment by Combination Products
- Androgen Antagonists Assessment by Route of Administration
- Androgen Antagonists Assessment by Stage and Route of Administration
- Androgen Antagonists Assessment by Molecule Type
- Androgen Antagonists Assessment by Stage and Molecule Type
- Androgen Antagonists Therapeutics - Discontinued Products
- Androgen Antagonists Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Androgen Antagonists by Therapy Area, 2017
- Number of Products under Development for Androgen Antagonists, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Androgen Antagonists Assessment by Monotherapy Products
- Androgen Antagonists Assessment by Combination Products
- Androgen Antagonists Assessment by Route of Administration
- Androgen Antagonists Assessment by Stage and Route of Administration
- Androgen Antagonists Assessment by Molecule Type
- Androgen Antagonists Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Hormone Replacement Therapy Market - Growth, Trends and Forecast (2017 - 2022)

Global Hormone Replacement Therapy Market - Growth, Trends and Forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The Global market for Hormone Replacement Therapy (HRT) Market is expected to reach $XX by the end of 2020 growing at a CAGR of around XX% from 2015 to 2021. Hormone Replacement therapy is the management ...

Breast Cancer Treatment Drug Markets in China

Breast Cancer Treatment Drug Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Breast Cancer Treatment Drug has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high ...

Prostate Cancer Treatment Drugs Markets in China

Prostate Cancer Treatment Drugs Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Prostate Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a ...


Download Unlimited Documents from Trusted Public Sources

Insulin Market and Diabetes Statistics in the US

  • March 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Therapy Market - Forecast

  • March 2017
    9 pages
  • Diabetes  

  • United States  

    Europe  

    Japan  

View report >

Related Market Segments :

Hormone

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.